維昌洋行（中國）有限公司日前宣布已與美國Sensus Healthcare，Inc簽訂新的獨家代理協議，在中國大陸和香港市場獨家代理銷售Sensus SRT-100系統。這也意味著維昌集團成為srt100淺層放射治療設備中國國內獨家代理經銷商。根據雙方約定，本獨家代理協議已經2021年1月1日起生效。srt100淺層放射治療設備目前在中國的公立和私立醫院以及私人診所裝機約40臺。Sensus期待維昌集團成為srt100淺層放射治療設備中國國內獨家代理經銷商后能更好的服務各級醫療機構，提高SRT-100淺層放射治療設備在國內的臨床應用和普及。

　　SRT-100系統使用了Sensus特有的低能量X射線技術，即淺層放射療法（SRT）。Ekpac Healthcare Technologies的總經理Julie Xue在評論該合作協議時說：“我們很高興Sensus Healthcare選擇Ekpac Healthcare作為為srt100淺層放射治療設備獨家代理商，并期待攜手合作，共同開拓SRT-100系統在中國的市場。維昌洋行在中國已有100多年的歷史，多年來成功將海外先進技術和設備結合國際融資引入中國。SRT-100淺層放射治療設備在疤痕疙瘩和非黑色素瘤皮膚癌治療方面具有獨特的特性和優勢，我們有信心取得成就，并將為中國的患者和社會帶來福音。”

　　“我們很高興維昌集團能成為srt100淺層放射治療設備中國國內的獨家代理經銷商。SRT-100淺層放射治療設備具有獨特的技術優勢，早在2013年美國FDA就對SRT-100出具證書，確認srt100淺層放射治療設備在疤痕治療方面具有絕對療效，中國擁有世界20%以上人口，在這個市場上我們看到了未來幾年乃至更長時間內的重大機遇。中國CFDA分別于2014年和2017年就批準了SRT-100用于治療非黑色素瘤皮膚癌和瘢痕疙瘩”。Benson Sun評論：“我們相信，維昌集團成為srt100淺層放射治療設備國內獨家代理經銷商后，憑借其在中國的大型醫療設備市場豐富的運營經驗和分銷網絡，他們能更好的服務各級醫療機構，推廣SRT-100淺層放射治療系統，為需要幫助的患者提供無創、高效和改變生活的解決方案。”

關于維昌
　　

      維昌美迪醫療技術（北京）有限公司隸屬于維昌洋行（中國）有限公司。維昌洋行成立于1910年，深耕中國市場100多年，是在國際上享有盛譽的百年企業。從80年代開始，隨著改革開放的大潮，維昌美迪醫療技術（北京）有限公司開始負責集團外國政府貸款醫療行業的業務，30多年來通過與國內各級醫療器械公司和醫療機構合作，共成功完成150多家國內醫院的項目，無論從數量還是執行質量，均在業界遙遙領先。

　　大約30年前，維昌集團開始專注于發展其醫療板塊業務，目前已為中國17個省份的150多家醫院提供服務。集團優勢在于利用全球的先進技術和產品來滿足中國的需求，同時利用其全球資源為客戶提供國際融資。在項目的執行過程中，維昌美迪醫療技術（北京）有限公司積累了豐富的項目經驗，與國外銀行、國內政府部門、全球主流供應商、國內醫院客戶建立了良好的合作關系，也成了很多國外企業、產品進入中國的橋梁。目前，維昌美迪醫療技術（北京）有限公司涵蓋維昌美迪醫療技術（北京）有限公司、維昌康健醫療器械（上海）有限公司、EKPAC Healthcare Limited及海外公司等多家獨立法人機構，業務范圍遍及歐美、日韓、東南亞、中國大陸和臺灣等地，業務領域也由單純的政府貸款發展到產品代理、出口信貸等業務多元化發展，業務領域涵蓋核醫學、內分泌、護理、檢驗、康復、放射、放療、神外等等。

聯系維昌

　　中國大陸地區SRT-100淺層放射治療設備考察引進及技術支持，請致電維昌美迪醫療技術（北京）有限公司。
　　銷售代表：張經理，電話：13911567019

 

---

附：Sensus Healthcare，Inc官網原文：

Agreement is for the treatment of non-melanoma skin cancer and keloids, covers China and Hong Kong and is effective January 1, 2021

BOCA RATON, Fla. (December 15, 2020) – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it has entered into a new exclusive distribution agreement with Ekpac Healthcare Ltd. to market Sensus SRT-100™ systems in China and Hong Kong. This agreement is effective as of January 1, 2021. Sensus currently has 40 units installed throughout China in public and private hospitals as well as private clinics. It expects this relationship to accelerate SRT-100 unit population in the region.
SRT-100 systems utilize Sensus’ proprietary low-energy x-ray technology known as superficial radiation therapy (SRT). China, which has more than 20% of the world’s population, approved the SRT-100 for the treatment of non-melanoma skin cancer and the prevention of scars following keloidectomy in 2014 and 2017, respectively. Sensus recently renewed its focus on international sales, including Asia, with the appointment of Benson Suen as Vice President International Sales July 2020.
Commenting on the agreement, Julie Xue, General Manager of Ekpac Healthcare Technologies, said, “We are delighted Sensus Healthcare has selected Ekpac Healthcare as its exclusive distributor, and look forward to working hand-in-hand to sell SRT-100 systems. Ekpac has more than 100 years of history in China, and is regarded as one of the most successful enterprises to bring advanced technology and devices – along with favorable financing – into China from overseas. SRT-100 systems have numerous compelling features and benefits. With the joint efforts of our two companies, we are confident tremendous success will be achieved and significant benefits will be delivered to patients across China.”
“We are excited to have Ekpac Healthcare as our partner in China, a market where we see significant opportunity over the next few years and beyond,” said Mr. Suen. “We believe that with Ekpac’s experience and their network for medical device distribution across China, they will be successful in selling SRT-100 machines to private clinics and public hospitals. In China and around the world, our systems offer non-invasive, highly efficacious and life-changing solutions to patients who are in need.”
About EKPAC Group
Ekpac Healthcare is part of EKPAC Group, which was founded in Sweden more than 110 years ago to import Swedish brands into China. Approximately 30 years ago Ekpac Healthcare began to focus on developing its healthcare business, and now supplies more than 150 hospitals in 17 provinces in China. Its strength is to bridge the latest needs in China with appropriate global advanced technologies, while leveraging its global network to provide clients with third-party financing for those technologies.